WG
CNCE

Winton Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Winton Group’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,648
Closed -$53K – 1516
2021
Q2 		$53K Buy
12,648
+549
+5% +$2.32K ﹤0.01% 1401
2021
Q1 		$60K Buy
+12,099
New +$97.8K ﹤0.01% 1348
2020
Q4 		– Sell
-31,506
Closed -$309K – 1570
2020
Q3 		$309K Sell
31,506
-28,007
-47% -$276K 0.01% 1237
2020
Q2 		$592K Sell
59,513
-1,132
-2% -$10.9K 0.02% 1150
2020
Q1 		$536K Sell
60,645
-28,057
-32% -$277K 0.01% 1009
2019
Q4 		$818K Buy
88,702
+61,327
+224% +$435K 0.01% 1113
2019
Q3 		$161K Buy
+27,375
New +$290K ﹤0.01% 1422

Other funds holding CNCE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Winton Group's CNCE Position: Q3 2021 in Review

Winton Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2021, closing a stake of 12,648 shares — an estimated $53K sold.

Winton Group first reported a position in CNCE in Q3 2019 and held it in 7 quarters. The position peaked at $818K in Q4 2019. 61 funds tracked by Wall St. Rank hold CNCE as of Q3 2021.

  • Winton Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Winton Group sold 12,648 Concert Pharmaceuticals, Inc. shares in Q3 2021, an estimated $53K.
  • Winton Group first reported a position in Concert Pharmaceuticals, Inc. in Q3 2019 and held it in 7 quarters.
  • Winton Group's Concert Pharmaceuticals, Inc. position peaked at $818K in Q4 2019.
  • 61 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2021.

Based on Winton Group's 13F filing for Q3 2021, filed 28 Oct 2021.